key: cord-0693271-44hzg2v4
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: COVID-19 with a heavily mutated variant in a multiple myeloma after vaccination: correspondence
date: 2022-01-07
journal: Clin Infect Pract
DOI: 10.1016/j.clinpr.2021.100132
sha: 63f551f024d2ead7e4f214809835a9f068a43917
doc_id: 693271
cord_uid: 44hzg2v4

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. [1] ." We agree that this patient with underlying myeloma had COVID-19 infection. Regardless of having multiple myeloma or not, any vaccinated person is at risk of becoming infected with a mutated variant. The efficacy of vaccines against variants of COVID-19 is still undergoing evaluation. Additionally, the effectiveness of standard two dose of COVID-19 vaccine among patients with underlying malignancy or other immunosuppression might be less than healthy people. The need for further vaccine boosters is being investigated and encouraged in many countries [2] .

Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination

Vaccine third dose and cancer patients: necessity or luxury? ESMO Open

The authors ask for waiving for any charge relating to this correspondence.